6,8-dibromo-5-methylimidazo[1,2-a]pyrazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡嗪类
• 英文名称: 6,8-dibromo-5-methylimidazo[1,2-a]pyrazine
• 英文别名: 6,8-Dibromo-5-methylimidazo[1,2-a]pyrazine
• 化学式: C₇H₅Br₂N₃
• 分子量: 290.945
• InChiKey: YIESLHWKUAAJIM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6,8-dibromo-5-methylimidazo[1,2-a]pyrazine 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 三乙胺 作用下， 以 乙醇 为溶剂， 78.0~100.0 ℃ 、689.47 kPa 条件下， 反应 21.0h， 生成 5-Methyl-8-(4-pyrimidin-2-yl-piperazin-1-yl)-imidazo[1,2-a]pyrazine-6-carboxylic acid methyl ester
  参考文献：
  名称：

  Small molecule inhibitors of IgE synthesis

  摘要：

  A novel series of small molecule inhibitors of IgE synthesis are described. Compounds were optimized for potency, metabolic stability and absence of genetic toxicology. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.05.042
• 作为产物：
  描述：

  2-氨基-6-甲基吡嗪 在 N-溴代丁二酰亚胺(NBS) 、 氢溴酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 20.25h， 生成 6,8-dibromo-5-methylimidazo[1,2-a]pyrazine
  参考文献：
  名称：

  SYK INHIBITORS

  摘要：

  本公开涉及一种用于治疗各种疾病状态的Syk抑制剂化合物，包括癌症和炎症性疾病。在特定实施例中，化合物的结构由式I给出：其中R1、R2、R3和R4如本文所述。本公开还提供了包括式I化合物或其药学上可接受的盐或共晶体的药物组合物，以及使用这些化合物和组合物治疗由Syk介导的疾病的方法。

  公开号：

  US20150175616A1

文献信息

• [EN] SYK INHIBITORS<br/>[FR] INHIBITEURS DE SYK
  申请人：GILEAD SCIENCES INC

  公开号：WO2016010809A1

  公开（公告）日：2016-01-21

  The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease slates, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein R1, R2, R3, and R4 are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk. In certain embodiments, also disclosed are methods for treating a cancer in a subject (e.g., a human) in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, in combination with a vinca-alkaloid, or a pharmaceutically acceptable salt thereof.

  本公开涉及一类Syk抑制剂化合物及其在治疗各种疾病状态中的应用，包括癌症和炎症性疾病。具体实施例中，该化合物的结构由公式I给出：其中R1、R2、R3和R4如本文所述。本公开还提供包括公式I化合物或其药学上可接受的盐的药物组合物，以及使用这些化合物和组合物治疗Syk介导的疾病的方法。在某些实施例中，还公开了治疗患有癌症的受试者（例如人类）的方法，包括向受试者施用一定量的公式I化合物或其药学上可接受的盐，与长春碱类药物或其药学上可接受的盐结合。
• SYK INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20150175616A1

  公开（公告）日：2015-06-25

  The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein R 1 , R 2 , R 3 , and R 4 are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts or co-crystals thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.

  本公开涉及一种用于治疗各种疾病状态的Syk抑制剂化合物，包括癌症和炎症性疾病。在特定实施例中，化合物的结构由式I给出：其中R1、R2、R3和R4如本文所述。本公开还提供了包括式I化合物或其药学上可接受的盐或共晶体的药物组合物，以及使用这些化合物和组合物治疗由Syk介导的疾病的方法。
• [EN] TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE WITH SYK INHIBITORS<br/>[FR] TRAITEMENT DE LA MALADIE CHRONIQUE DU GREFFON CONTRE L'HÔTE AVEC INHIBITEURS SYK
  申请人：GILEAD SCIENCES INC

  公开号：WO2016172117A1

  公开（公告）日：2016-10-27

  The present disclosure provides methods of utilizing Syk inhibiting compounds in the treatment for graft versus host disease (GVHD) in a human, including acute graft versus host disease (aGVHD) and chronic graft versus host disease (cGVHD), including the use of compounds selected from the group consisting of the formulas below: (I) and (II).

  本公开提供了在人类中利用Syk抑制化合物治疗移植物抗宿主病（GVHD）的方法，包括急性移植物抗宿主病（aGVHD）和慢性移植物抗宿主病（cGVHD），包括使用从以下公式组中选择的化合物：(I)和(II)。
• Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
  申请人：Gilead Sciences, Inc.

  公开号：US09290505B2

  公开（公告）日：2016-03-22

  The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein R1, R2, R3, and R4 are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts or co-crystals thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.

  本公开涉及的化合物是Syk抑制剂及其在治疗各种疾病状态中的应用，包括癌症和炎症疾病。在特定实施例中，化合物的结构由式I给出：其中R1、R2、R3和R4如本文所述。本公开进一步提供包括式I化合物或其药学上可接受的盐或共晶体的制药组合物以及使用这些化合物和组合物治疗Syk介导的疾病的方法。
• TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE WITH SYK INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20160375019A1

  公开（公告）日：2016-12-29

  The present disclosure provides methods of utilizing Syk inhibiting compounds in the treatment for graft versus host disease (GVHD) in a human, including acute graft versus host disease (aGVHD) and chronic graft versus host disease (cGVHD), including the use of compounds selected from the group consisting of the formulas below: